Pharmaceutical companies that develop new medicines for life-threatening or severely debilitating conditions could be eligible to file for a priority review in the five ACCESS Consortium member countries under a new pilot scheme.
The ACCESS Consortium, an international coalition made up of the regulatory agencies for Australia, Canada, Singapore, Switzerland and the UK, has outlined how its new “promise pilot” pathway will work in practice and which types of medicines are eligible for this assessment route.
The promise pilot pathway is a priority review scheme for new medicines that meet certain criteria, such as treating a...
Create an account to read this article
Already a subscriber?
The World Health Organization wants vaccine manufacturers and the scientific community to share certain types of data before its Technical Advisory Group on COVID-19 Vaccine Composition meets in December.
The European Commission, Parliament and Council should be mindful of ‘significant new risks’ posed by MFN drug pricing in the US during negotiations that will shape the bloc’s pharmaceutical legislation, a lawyer from Sidley Austin says.
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
Canada’s drug regulator is using amended drug laws to increase the use of regulatory reliance pathways to improve efficiency and support international alignment, while the UK’s MHRA has held talks with Australia’s TGA on topics including the role of AI in regulatory frameworks.
Claims for the dermatological appearing on websites and social media were challenged by Dupixent marketer Sanofi. Galderma said it would comply with the National Advertising Division’s recommendations, a move that underscores the challenging times for DTC advertisers.
India rolls out amended R&D financial assistance plan targeting certain ‘priority areas’ and calls for proposals from industry and startups. While the corpus is modest, the scheme hopes to enable the ‘Innovate in India’ ecosystem and includes a co-funding provision.
Revision of the EU’s pharmaceutical legislation will include a new definition of unmet need, but getting it wrong could have unintended consequences for pricing and reimbursement.
